Deerfield Management Company, L.P. (Series C) Cyma Bay Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CBAY
# of Institutions
6Shares Held
1.82MCall Options Held
0Put Options Held
0-
Foresite Capital Management Iii, LLC Larkspur, CA1.64MShares$015.17% of portfolio
-
Abingworth LLP London, X0131KShares$00.27% of portfolio
-
Connacht Asset Management LP New York, NY12KShares$01.09% of portfolio
-
Ctc Capital Management, LLC10.7KShares$00.2% of portfolio
-
Pictet Asset Management Sa Geneva 73, V810.6KShares$00.0% of portfolio
About CymaBay Therapeutics, Inc.
- Ticker CBAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,677,904
- Description
- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...